One of the key aims of PREDICT-Meso is generation and characterisation of new mesothelioma models (work package 3) and making these available to the research community, including to test validation of drug-target combinations (work package 4)

Target Drug Validation (TDV) requests are reviewed by a highly skilled Models Access Board (MAB) to ensure that the approved application has scientific value and is an appropriate use of the models.

We have recently had a successful TDV application from researchers at Vector Bioscience Cambridge who will develop a novel nanocarrier-based formulation specifically designed to address the challenges of mesothelioma treatment.

The formulation aims to enable targeted delivery and controlled release of therapeutic agents, with the goal of improving efficacy while reducing toxicity. Targeted delivery is particularly relevant in mesothelioma, where localised drug release may help limit side effects and overcome the limited penetration of conventional therapies.

An initial study will focus on efficacy and preliminary safety outputs with further, more expansive follow up studies in a subsequent phase.

See the Bioscience Cambridge blog at the button below for more info